EMA reviews Gilenya deaths links, backs Novartis Cushing's drug
The latest set of opinions from the European Medicines Agency has been dominated by the news that a…See More
Pharmaceutical Social Network
PharmaBusiness.com
Pharmaceutical Social Network. Business information services for the medical and pharmaceutical industries and professionals.
Latest Activity
US FDA sends three drug user fee programmes to Congress
The US Food and Drug Administration (FDA) has now sent its proposals for three prescription drug…See More
Discussion posted by Nicolás Mena
Novartis cuts nearly 2,000 jobs in USA, takes major charges
Novartis is to axe 1,960 jobs as part of a restructuring of its US operations, prompted by the…See More
Discussion posted by Elisa Marferson
No more mega-acquisitions for Pfizer, claims CEO
Pfizer is highly unlikely to pursue any mega-mergers but will continue to look at bolt-on…See More
Discussion posted by Michael Honatan
B-MS to buy HCV firm Inhibitex in $2.50 billion deal
Bristol-Myers Squibb has hit the acquisition trail and unveiled plans to buy hepatitis C specialist…See More
Discussion posted by Nicolás Mena
Groups
-
Pfizer
22 members
-
Bayer
19 members
-
Novartis
18 members
-
Sanofi Aventis
15 members
-
ROCHE
14 members
-
Merck
13 members
-
Eli Lilly
13 members
-
GlaxoSmithKline
12 members
-
Jobs
12 members
-
PARC CIENTÍFIC BARCELONA…
11 members
Forum
EMA reviews Gilenya deaths links, backs Novartis Cushing's drug
Started by Pharmaceutical on Monday. 0 Replies 0 Likes
The latest set of opinions from the European Medicines Agency has been dominated by the news that a safety review of the benefits and risks of Novartis' oral multiple sclerosis treatment Gilenya has begun.The agency's Committee for Medicinal…Continue
US FDA sends three drug user fee programmes to Congress
Started by Nicolás Mena Jan 16. 0 Replies 0 Likes
The US Food and Drug Administration (FDA) has now sent its proposals for three prescription drug user fee programmes to Congress.They are the fifth authorisation of the Prescription Drug User Fee Act (PDUFA-V), plus two new programmes for human-use…Continue
Tags: fee, programmes, to, Congress, user
Novartis cuts nearly 2,000 jobs in USA, takes major charges
Started by Elisa Marferson Jan 13. 0 Replies 0 Likes
Novartis is to axe 1,960 jobs as part of a restructuring of its US operations, prompted by the pending patent loss on its hypertension blockbuster Diovan and predicted lower sales of the blood pressure drug Tekturna/Rasilez.The Swiss major said its…Continue
No more mega-acquisitions for Pfizer, claims CEO
Started by Michael Honatan Jan 11. 0 Replies 0 Likes
Pfizer is highly unlikely to pursue any mega-mergers but will continue to look at bolt-on acquisitions and more research alliances, according to chief executive Ian Read.Speaking at the JP Morgan Global Healthcare Conference in San Francisco, Mr…Continue
Featured Events
April 18
Wednesday
Featured news
D-Day for Lipitor as scramble for US market share begins
Posted by Nicolás Mena on November 30, 2011 at 9:51pm 0 Comments 0 Likes
Lipitor, the world's best-selling drug, goes off-patent in the USA today, and observers are watching keenly to see how damaging the loss will be to Pfizer and how much generics firms will benefit.
Pfizer is fighting hard to keep hold of a…
Continue Novartis triple-combo blood pressure drug gets European OK
Posted by Elisa Marferson on November 28, 2011 at 11:55pm 0 Comments 0 Likes
Novartis has been given the green light to market its triple combination antihypertensive Rasitrio.
The European Commission has approved Rasitrio as a single pill for the treatment of high blood pressure. It combines the Swiss…
Continue Facebook in firing line over tale of two Mercks
Posted by Michael Honatan on November 24, 2011 at 8:56pm 0 Comments 0 Likes
Germany's Merck KGaA has asked a New York judge to force Facebook to provide information about "an apparent takeover" of its page on the social networking site, which is now occupied by information on rival Merck & Co.
Robert Horowitz…
Continue EU approves Pfizer's Vyndaqel, FDA backs Prevnar 13 expansion
Posted by Nicolás Mena on November 17, 2011 at 9:15pm 0 Comments 0 Likes
The European Commission has approved Pfizer's Vyndaqel for the treatment of a rare genetic disease.
Vyndaqel (tafamidis) has been given the green light for transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressive and fatal…
Continue US CBO doubles estimated savings from pay-for-delay ban
Posted by Nicolás Mena on November 14, 2011 at 8:29pm 0 Comments 0 Likes
The US Congressional Budget Office (CBO) now estimates that banning "pay-for-delay" deals between brand-name and generic drugmakers would reduce the federal deficit by $4.8 billion over 10 years; last year it said the measure would cut…
Continue AstraZeneca/Targacept antidepressant fails Phase III study
Posted by Nicolás Mena on November 8, 2011 at 8:18pm 0 Comments 0 Likes
AstraZeneca and partner Targacept have announced disappointing top-line results from the first of four late-stage studies on their new antidepressant.
Specifically, the Renaissance 3 Phase III study investigated TC-5214 as an adjunct…
Continue
Videos
Badge
© 2012 Created by ROSMA.
